HUP0100819A2 - Aminofenoxiecetsavszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Aminofenoxiecetsavszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0100819A2
HUP0100819A2 HU0100819A HUP0100819A HUP0100819A2 HU P0100819 A2 HUP0100819 A2 HU P0100819A2 HU 0100819 A HU0100819 A HU 0100819A HU P0100819 A HUP0100819 A HU P0100819A HU P0100819 A2 HUP0100819 A2 HU P0100819A2
Authority
HU
Hungary
Prior art keywords
optionally substituted
group
atom
oxygen
formula
Prior art date
Application number
HU0100819A
Other languages
English (en)
Inventor
Hirokazu Annoura
Naohiro Takemoto
Hiroshi Uramoto
Original Assignee
Suntory Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Limited filed Critical Suntory Limited
Publication of HUP0100819A2 publication Critical patent/HUP0100819A2/hu
Publication of HUP0100819A3 publication Critical patent/HUP0100819A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány új aminofenoxiecetsav-származékokra és ezek gyógyá-szatilag elfogadható sóira vonatkozik, amelyeknek neuroprotektívhatásuk van azáltal, hogy kiváltják vagy fokozzák a calbindin D28Kd,azaz az egyik kalciumion-megkötő fehérje képződését, ezért ezek avegyületek felhasználhatók az agyban funkcionális és organikus eredetűrendellenességek kezelésére és enyhítésére. A találmány szerintivegyületek (I) általános képletében R1, R2, R3 és R4 egymástólfüggetlenül hidrogén- vagy halogénatomot vagy hidroxi-, adott esetbenhelyettesített alkoxi-, adott esetben helyettesített alkil-, adottesetben helyettesített aril- vagy adott esetben helyettesítettaralkilcsoportot jelent; R5, R6, R7 és R8 egymástól függetlenülhidrogénatomot vagy adott esetben helyettesített alkil-, adott esetbenhelyettesített aril- vagy adott esetben helyettesítettaralkilcsoportot jelent; E1 jelentése oxigén- vagy kénatom vagy -NR9-általános képletű csoport (ebben a képletben R9 jelentése hidrogénatomvagy adott esetben helyettesített alkil-, adott esetben helyettesítettaril- vagy adott esetben helyettesített aralkilcsoport); E2 jelentéseoxigén- vagy kénatom vagy -NR10- általános képletű csoport (ebben aképletben R10 jelentése hidrogénatom vagy adott esetben helyettesítettalkil-, adott esetben helyettesített aril- vagy adott esetbenhelyettesített aralkilcsoport); n értéke 0, 1, 2, 3, 4 vagy 5; X és Yegymástól függetlenül kémiai kötést vagy hidroxilcsoporttal adottesetben szubsztituált alkiléncsoportot, cikloalkiléncsoportot, rövidszénláncú alkilcsoporttal adott esetben helyettesítettalkeniléncsoportot vagy -NHCO-, -CONH- vagy -SO2- képletű csoportotjelent; Q jelentése hidrogénatom vagy adott esetben szubsztituáltfenil-, adott esetben szubsztituált fenoxi-, adott esetbenszubsztituált benzoil-, adott esetben szubsztituált piridil-, adottesetben szubsztituált kinolil-, adott esetben szubsztituáltizokinolil- vagy adott esetben szubsztituált benzimidazolilcsoport;azzal a megkötéssel, hogy ha E1 és E2 közül az egyik oxigén- vagykénatomot jelent, akkor a másik jelentése egyidejűleg oxigén- vagykénatomtól eltérő, és ha E1 jelentése nitrogénatom és E2 jelentéseoxigénatom, vagy ha E1 jelentése oxigénatom és E2 jelentésenitrogénatom, akkor R1, R2, R3 és R4 egyidejű jelentésemetilcsoporttól eltérő. Ó
HU0100819A 1998-10-16 1999-10-14 Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical compositions containing them HUP0100819A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29488698 1998-10-16
PCT/JP1999/005658 WO2000023076A1 (en) 1998-10-16 1999-10-14 Aminophenoxyacetic acid derivatives as neuroprotectants

Publications (2)

Publication Number Publication Date
HUP0100819A2 true HUP0100819A2 (hu) 2001-08-28
HUP0100819A3 HUP0100819A3 (en) 2002-12-28

Family

ID=17813532

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100819A HUP0100819A3 (en) 1998-10-16 1999-10-14 Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical compositions containing them

Country Status (12)

Country Link
US (3) US6559146B1 (hu)
EP (1) EP1045693B1 (hu)
JP (1) JP2002527477A (hu)
KR (1) KR100676109B1 (hu)
CN (1) CN1198613C (hu)
AT (1) ATE270103T1 (hu)
AU (1) AU762345B2 (hu)
CA (1) CA2315050C (hu)
DE (1) DE69918404T2 (hu)
ES (1) ES2221440T3 (hu)
HU (1) HUP0100819A3 (hu)
WO (1) WO2000023076A1 (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198613C (zh) * 1998-10-16 2005-04-27 第一三得利制药株式会社 氨基苯氧基乙酸衍生物和含有它们的药用组合物
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
EP1263729B1 (en) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
AU784930B2 (en) * 2000-04-13 2006-08-03 Asubio Pharma Co., Ltd. Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
EP1313713B1 (en) * 2000-08-08 2008-06-11 Ortho-McNeil Pharmaceutical, Inc. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US6911452B2 (en) 2001-12-28 2005-06-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR101095939B1 (ko) 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
AU2005289635A1 (en) 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US8068569B2 (en) 2005-10-05 2011-11-29 Lg Electronics, Inc. Method and apparatus for signal processing and encoding and decoding
KR100857121B1 (ko) 2005-10-05 2008-09-05 엘지전자 주식회사 신호 처리 방법 및 이의 장치, 그리고 인코딩 및 디코딩방법 및 이의 장치
EP1946062A4 (en) 2005-10-05 2009-09-09 Lg Electronics Inc METHOD AND DEVICE FOR SIGNAL PROCESSING AND CODING AND DECODING METHOD AND DEVICE THEREFOR
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
CN101677971A (zh) 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP2679586B1 (en) * 2007-04-27 2016-02-10 Daiichi Sankyo Company, Limited Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3468960B1 (en) 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
US20210130308A1 (en) * 2018-03-23 2021-05-06 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214147A (en) * 1987-08-12 1993-05-25 Elf Atochem North America, Inc. Process for preparing reactive hindered amine light stabilizers
ATE133942T1 (de) 1987-11-27 1996-02-15 Eisai Co Ltd Cyclische amine und pharmakologische verbindungen
DE4032766A1 (de) * 1990-10-16 1992-04-30 Basf Ag Phenylpiperidinoylamine und diese enthaltende arzneimittel
IL105716A0 (en) 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
KR19990037220A (ko) 1997-10-31 1999-05-25 타이도 나오카타 아릴아세트산 아미드 유도체 또는 그 염 및 이를 함유하는 의약
CN1198613C (zh) * 1998-10-16 2005-04-27 第一三得利制药株式会社 氨基苯氧基乙酸衍生物和含有它们的药用组合物

Also Published As

Publication number Publication date
US7488738B2 (en) 2009-02-10
KR20010033169A (ko) 2001-04-25
ATE270103T1 (de) 2004-07-15
WO2000023076A1 (en) 2000-04-27
US6559146B1 (en) 2003-05-06
CN1287487A (zh) 2001-03-14
US20040063748A1 (en) 2004-04-01
KR100676109B1 (ko) 2007-02-01
JP2002527477A (ja) 2002-08-27
HUP0100819A3 (en) 2002-12-28
DE69918404T2 (de) 2005-08-04
US20050245574A1 (en) 2005-11-03
US6998401B2 (en) 2006-02-14
CA2315050C (en) 2009-02-03
EP1045693A1 (en) 2000-10-25
CN1198613C (zh) 2005-04-27
AU762345B2 (en) 2003-06-26
AU6122699A (en) 2000-05-08
DE69918404D1 (de) 2004-08-05
EP1045693B1 (en) 2004-06-30
ES2221440T3 (es) 2004-12-16
CA2315050A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
HUP0100819A2 (hu) Aminofenoxiecetsavszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
BRPI0616799B8 (pt) derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
HUP0301382A2 (hu) Alfa-aril-etanol-amin-származékok és e vegyületeket tartalmazó béta-3 adrenergiás receptor agonista hatású gyógyászati készítmények
HUP0202703A2 (hu) Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0203228A2 (hu) Szubsztituált indolszármazékok az NFKB-aktivitás módosítására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE421322T1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
KR880006229A (ko) 항궤양 활성을 갖는 피리딘 유도체
HUP0204283A2 (hu) (Kinolil-propil)-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0105437A2 (hu) Új malonsavszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE374763T1 (de) Bisarylsulfonamid-derivate und ihre verwendung für krebs therapie
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
AR029151A1 (es) Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene
KR850000462A (ko) [[비스(아릴)메틸렌]-1-피페리디닐]알킬-피리미딘온의 제조방법
BR9916491A (pt) 4-(aminometil)-piperidina benzamidas para tratamento de distúrbios gastrintestinais
CY1111909T1 (el) Παραγωγα [[2-(αμινο-3,4-διοξο-1-κυκλοβουτεν-1-υλ)amino] αλκυλ]-οξεος για τη θεραπεια του πονου
DK0541798T3 (da) Hidtil ukendt diaminforbindelse og cerebralbeskyttende middel indeholdende denne
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
KR920019738A (ko) 아미디노페닐알라닌 유도체, 이의 제조방법, 용도 및 이를 함유하는 조성물
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
ATE267816T1 (de) Tan-1057 derivate

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ASUBIO PHARMA CO., LTD., JP

Free format text: FORMER OWNER(S): SUNTORY LIMITED, JP; DAIICHI ASUBIO PHARMA CO., LTD., JP; DAIICHI SUNTORY PHARMA CO., LTD., JP

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished